

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists, NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

Dear Healthcare Professional,

DRUG ALERTS NO 26 – CLASS 2

Please find attached revised drug safety information from the Medicines and Healthcare Products Regulatory Agency (MHRA) for onward transmission (see list below).

1. Please could Directors of Pharmacy forward this alert to:-
 - Hospital pharmacists
 - Chief Pharmacists to forward on to Medicines Information Pharmacists
 - Community pharmacists
2. Please could Medical Directors forward the message on to :-
 - General Practitioners
 - Dispensing Doctors
 - Immunisation coordinators
 - Chief Executives NHS Boards

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Pharmacy Division

* NB: Drug alerts have the following classifications:

1. Action now (including out-of-hours);
2. Action within 48 hours;
3. Action within 5 days;
4. Caution in use



Safeguarding public health

**Defective Medicines Report Centre
Market Towers
1 Nine Elms Lane
London
SW8 5NQ
Telephone: +44 (0)20 7084 2574**

Fax: +44 (0)20 7084 2676

DRUG ALERT

CLASS 2 MEDICINES RECALL

**Action Within 48 Hours
PHARMACY OR EQUIVALENT LEVEL RECALL**

Date: 29 September 2009

EL (09)A/26

Our Ref: MDR 71-09/09

Dear Healthcare Professional,

GlaxoSmithKline Biologicals sa

**Cervarix suspension for injection in pre-filled syringes
(Human Papillomavirus vaccine)**

Eu/1/07/419/004

Batch Number	Expiry Date	Pack Size	First Distributed
AHPVA043BB	09/2010	1 Syringe + needle	01 May 2009

Following the tragic death of a young girl, who had received vaccination from the above batch of Cervarix, the Department of Health has issued a quarantine notification.

As a further precautionary measure, GlaxoSmithKline Biologicals sa is now undertaking a voluntary recall of the above batch of Cervarix pending further investigation.

Please quarantine any remaining stocks of this batch. Movianto UK Ltd will contact customers directly regarding stock and the details of the product to be collected. Movianto can be contacted by email (customer care.uk@movianto.co.uk).

The risk benefit assessment for the vaccine remains unchanged; there is currently no proven link between vaccination and the event and the HPV vaccination programme will continue.

No other batches are affected by this recall. Further stocks of vaccine from different batches can be ordered in the usual way.

MHRA Distribution:

Regional Contacts for NHS Trusts and Provider Units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency
Market Towers 1 Nine Elms Lane London SW8 5NQ
T 020 7084 2000 F 020 7084 2353 www.mhra.gov.uk

An executive agency of the Department of Health



Date: 29 September 2009

EL (09)A/26

MDR 71-09/09

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant distribution centres and immunisation teams.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor, DMRC